Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage
Ammar AA, Ammar MA, Owusu KA, Brown SC, Kaddouh F, Elsamadicy AA, Acosta JN, Falcone GJ. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage. Neurocritical Care 2021, 35: 255-261. PMID: 33403588, PMCID: PMC10273779, DOI: 10.1007/s12028-020-01161-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnticoagulantsBlood Coagulation FactorsFactor XaFactor Xa InhibitorsFemaleHumansInfant, NewbornIntracranial HemorrhagesMaleRecombinant ProteinsRetrospective StudiesConceptsFactor Xa inhibitorsSpontaneous intracranial hemorrhageSpontaneous intraparenchymal hemorrhageAndexanet alfaIntracranial hemorrhageProthrombin complex concentrateThrombotic eventsIntraparenchymal hemorrhageFunctional outcomeComplex concentrateXa inhibitorsFour-factor prothrombin complex concentrateOnset of ICHConsecutive adult patientsGood functional outcomeModified Rankin scoreSubgroup of patientsNumber of patientsThromboembolic eventsRankin scoreAdult patientsMedian ageRetrospective reviewHematoma volumeResultsA total